FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304332> ?p ?o ?g. }

• W4367304332 abstract "<h3>Objective:</h3> To confirm the prevalence of anti-immunoglobulin-like cell adhesion molecule 5 (IgLON5) disease in patients who fulfill the diagnostic criteria for progressive supranuclear palsy (PSP) or corticobasal syndrome (CBS). <h3>Background:</h3> Anti-IgLON5 disease can present symptoms that mimic PSP and CBS, including vertical supranuclear gaze palsy and parkinsonism. Some patients who are diagnosed with PSP or CBS are expected to have anti-IgLON5 antibodies; however, the frequency of such patients remains unknown. <h3>Design/Methods:</h3> We included 360 subjects enrolled in the Japanese Longitudinal Biomarker Study in PSP and Corticobasal Degeneration (JALPAC). We noted the age and sex of each patient and evaluated their diagnosis using diagnostic criteria for each subtype of PSP (PSP with Richardson’s syndrome [PSP-RS], PSP with parkinsonism [PSP-P], PSP-pure akinesia with gait freezing [PSP-PAGF], and PSP with cerebellar ataxia [PSP-C]), and using the revised Cambridge criteria and Armstrong criteria for CBS. In patients who fulfilled any diagnostic criteria, we then tested serum anti-IgLON5 antibodies via a cell-based assay. <h3>Results:</h3> Of 360 subjects in JALPAC, 223 fulfilled at least one of the diagnostic criteria for possible or probable PSP/CBS. The median age of these 223 patients was 73 (range 51–88) years; 123 (55%) were male. The numbers of patients who met each set of criteria were as follows: PSP-RS, 52; PSP-PAGF, 6; PSP-C, 2; CBS, 117; PSP-RS and CBS, 37; PSP-PAGF and CBS, 4; PSP-RS and PSP-PAGF, 1; PSP-RS and PSP-P, 1; PSP-P and CBS, 1; PSP-RS, PSP-PAGF, and CBS, 1; and PSP-RS, PSP-C, and CBS, 1. All 223 patients were negative for anti-IgLON5 antibodies. <h3>Conclusions:</h3> Anti-IgLON5 disease is likely absent or extremely rare in patients who meet the diagnostic criteria for PSP/CBS and have typical clinical presentations. Atypical symptoms such as sleep disturbance, dysautonomia, and respiratory failure may be crucial clinical features of anti-IgLON5 disease with PSP-/CBS-like presentations. <b>Disclosure:</b> Yoya Ono has nothing to disclose. Akira Takekoshi has nothing to disclose. Dr. Yoshikura has nothing to disclose. Dr. Takigawa has nothing to disclose. Ikuko Aiba has nothing to disclose. Ritsuko Hanajima has nothing to disclose. Dr. Kowa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for DAIICHI SANKYO COMPANY, LIMITED. Dr. Kowa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly Japan K.K.. Dr. Kowa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Otsuka Pharmaceutical Co., Ltd.. Dr. Kowa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen Inc.. Dr. Kowa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda Pharmaceutical Company Limited.. Dr. Kowa has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Kyowa Kirin Co., Ltd.. Dr. Kowa has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Chugai Pharmaceutical Co., Ltd.. Dr. Kowa has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for ONO PHARMACEUTICAL CO., LTD.. Dr. Kanazawa has nothing to disclose. Dr. ?? has nothing to disclose. Aya Tokumaru has nothing to disclose. Dr. Morita has nothing to disclose. Dr. Hasegawa has nothing to disclose. Kenji Nakashima has nothing to disclose. Dr. Ikeuchi has nothing to disclose. Dr. Kimura has nothing to disclose. Dr. Shimohata has nothing to disclose." @default.
• W4367304332 created "2023-04-29" @default.
• W4367304332 creator A5007458112 @default.
• W4367304332 creator A5011944567 @default.
• W4367304332 creator A5016832148 @default.
• W4367304332 creator A5023346646 @default.
• W4367304332 creator A5027676152 @default.
• W4367304332 creator A5034256687 @default.
• W4367304332 creator A5036650217 @default.
• W4367304332 creator A5038009551 @default.
• W4367304332 creator A5038583998 @default.
• W4367304332 creator A5038662554 @default.
• W4367304332 creator A5041282119 @default.
• W4367304332 creator A5051746428 @default.
• W4367304332 creator A5062786061 @default.
• W4367304332 creator A5068087815 @default.
• W4367304332 creator A5068849863 @default.
• W4367304332 creator A5075135713 @default.
• W4367304332 date "2023-04-25" @default.
• W4367304332 modified "2023-09-30" @default.
• W4367304332 title "Frequency of anti-IgLON5 disease in patients who meet the clinical diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (S22.010)" @default.
• W4367304332 doi "https://doi.org/10.1212/wnl.0000000000202665" @default.
• W4367304332 hasPublicationYear "2023" @default.
• W4367304332 type Work @default.
• W4367304332 citedByCount "0" @default.
• W4367304332 crossrefType "proceedings-article" @default.
• W4367304332 hasAuthorship W4367304332A5007458112 @default.
• W4367304332 hasAuthorship W4367304332A5011944567 @default.
• W4367304332 hasAuthorship W4367304332A5016832148 @default.
• W4367304332 hasAuthorship W4367304332A5023346646 @default.
• W4367304332 hasAuthorship W4367304332A5027676152 @default.
• W4367304332 hasAuthorship W4367304332A5034256687 @default.
• W4367304332 hasAuthorship W4367304332A5036650217 @default.
• W4367304332 hasAuthorship W4367304332A5038009551 @default.
• W4367304332 hasAuthorship W4367304332A5038583998 @default.
• W4367304332 hasAuthorship W4367304332A5038662554 @default.
• W4367304332 hasAuthorship W4367304332A5041282119 @default.
• W4367304332 hasAuthorship W4367304332A5051746428 @default.
• W4367304332 hasAuthorship W4367304332A5062786061 @default.
• W4367304332 hasAuthorship W4367304332A5068087815 @default.
• W4367304332 hasAuthorship W4367304332A5068849863 @default.
• W4367304332 hasAuthorship W4367304332A5075135713 @default.
• W4367304332 hasConcept C126322002 @default.
• W4367304332 hasConcept C142724271 @default.
• W4367304332 hasConcept C187212893 @default.
• W4367304332 hasConcept C2776477761 @default.
• W4367304332 hasConcept C2776525014 @default.
• W4367304332 hasConcept C2776936178 @default.
• W4367304332 hasConcept C2778261627 @default.
• W4367304332 hasConcept C2779134260 @default.
• W4367304332 hasConcept C71924100 @default.
• W4367304332 hasConceptScore W4367304332C126322002 @default.
• W4367304332 hasConceptScore W4367304332C142724271 @default.
• W4367304332 hasConceptScore W4367304332C187212893 @default.
• W4367304332 hasConceptScore W4367304332C2776477761 @default.
• W4367304332 hasConceptScore W4367304332C2776525014 @default.
• W4367304332 hasConceptScore W4367304332C2776936178 @default.
• W4367304332 hasConceptScore W4367304332C2778261627 @default.
• W4367304332 hasConceptScore W4367304332C2779134260 @default.
• W4367304332 hasConceptScore W4367304332C71924100 @default.
• W4367304332 hasLocation W43673043321 @default.
• W4367304332 hasOpenAccess W4367304332 @default.
• W4367304332 hasPrimaryLocation W43673043321 @default.
• W4367304332 hasRelatedWork W124854678 @default.
• W4367304332 hasRelatedWork W1972317130 @default.
• W4367304332 hasRelatedWork W2045924744 @default.
• W4367304332 hasRelatedWork W2054367000 @default.
• W4367304332 hasRelatedWork W2068005417 @default.
• W4367304332 hasRelatedWork W2076110754 @default.
• W4367304332 hasRelatedWork W2987609702 @default.
• W4367304332 hasRelatedWork W3011502412 @default.
• W4367304332 hasRelatedWork W4296640235 @default.
• W4367304332 hasRelatedWork W210321392 @default.
• W4367304332 isParatext "false" @default.
• W4367304332 isRetracted "false" @default.
• W4367304332 workType "article" @default.